Up 45% in 2012 and nearly 70% in the past 12 months, Danish pharmaceutical company Novo Nordisk (NYSE:NVO) has outpaced its peers by a wide margin. Novo's performance has been fueled by an incredibly concerning trend, the growing incidence of diabetes worldwide. As the leader in insulin -- a must-have for Type 1 diabetes patients and a growing need for many Type 2 diabetics -- the company is well-positioned to capitalize on this secular trend.

In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss some more positive news for Novo Nordisk, as well as an important date for investors to be aware of next month. 

Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.